



Contact:

Robert Gottlieb
RMG Associates, LLC
857-891-9091
Robertmg52@gmail.com

Cellanyx presents at 2017 International Cancer Cluster Showcase at BIO, 2017.

Beverly, MA, July 19, 2017 – Cellanyx’s live cell phenotypic biomarker test data demonstrating the potential to stratify prostate cancer risk from ‘normal’ [field] was presented at the [2017 International Cancer Cluster Showcase at BIO, 2017](#). Cutting edge oncology innovations from leading North American and European industry clusters were presented in compact presentations, giving attendees a chance to quickly learn about cutting-edge work at the forefront of oncology.

About Cellanyx

Cellanyx is developing a proprietary living cell phenotypic cancer diagnostic platform to aid clinical decision making. The company’s unique ‘biopsy-on-a-chip’ methodology provides quantitative, actionable assessment of individual cancer cells in biopsy samples using multiple phenotypic biochemical and biophysical markers of tumor aggressiveness and metastatic potential. Cellanyx has demonstrated clinical proof-of-concept with its lead product in development, a diagnostic to improve risk stratification in men with prostate cancer. Learn more at www.cellanyx.com.

Contact:

Ashok Chander, CEO
ashok@cellanyx.com
978 473 7883

Robert Gottlieb, RMG Associates, LLC
Robertmg52@gmail.com
857 891 9091

###